52 Week Range
As of on the National Stock Exchange of India ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Sun Pharma To Buy Stake In WRS Bioproducts For A$2 Mln
Sun Pharma Says Global Specialty Sales Have Crossed Pre-COVID Levels In Qtr
India's Sun Pharma Dec-Qtr Consol Net PAT Jumps
Sun Pharmaceutical Industries Limited is a pharmaceuticals company. The Company's business segments include US Business, Indian Branded Generics Business, Emerging Markets, Global Consumer Healthcare Business and Active Pharmaceutical Ingredients (API). Its Rest of World segment includes Western Europe, Canada, Australia, New Zealand and other markets. The Company offers its products to therapy areas, such as cardiology, neuro-psychiatry, gastroenterology, anti-infective, diabetology and dermatology. The Company's products include AB PHYLLINE, ABZORB DUSTING POWDER, ACAMPROL, ACOSTIN 3 MIU, ACOSTIN FORTE and AB PHYLLINE SR 200. Its manufacturing units are situated in India, the United States and Brazil, among others. Its units produce generics, branded generics, specialty products, over-the-counter (OTC) products, anti-retroviral (ARVs) and APIs. They also produce intermediates in a range of dosage forms, including tablets, capsules, injectables, ointments, creams and liquids.
Biotechnology & Drugs
Andheri Kurla Road, Andheri East
Non-Executive Chairman of the Board
C. S. Muralidharan
Chief Financial Officer
Chief Executive Officer - Taro Pharmaceutical Industries Limited
Chief Executive Officer - North America
Chief Executive Officer - India Business
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
India's Sun Pharmaceutical Industries Ltd said on Tuesday it would soon begin selling its version of favipiravir, becoming the latest generic drugmaker to supply the antiviral to treat COVID-19 in the world's third worst-hit nation.
Sun Pharmaceutical Industries Ltd's U.S. subsidiary said on Friday it had donated 2.5 million hydroxychloroquine sulfate tablets as a potential treatment for the rapidly spreading coronavirus.
A subsidiary of India's Sun Pharmaceutical Industries Ltd said on Friday it had donated 2.5 million hydroxychloroquine sulfate tablets in the United States as a potential treatment for coronavirus.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.